Onyx Pharmaceuticals: FDA grants priority review status colorectal cancer drug regorafenib
Onyx biopharmaceutical its partners Bayer (Bayer)'s Bayer HealthCare (Bayer Healthcare) jointly announced, FDA granted regorafenib (BAY 73-4506) priority review status.
Bayer Healthcare was submitted to the FDA by the end of April this year, regorafenib New Drug Application (NDA), for the illness after receiving standard therapy for metastatic colorectal cancer patients is still deteriorating.
Regorafenib oral medication is a multi-kinase inhibitor, the company is now a variety of cancer patients for clinical trials to investigate its therapeutic potential in research.
FDA grants priority review status for existing drugs usually with little or no appropriate therapies to treat the disease. In addition, priority review status means that medication review period from the standard 10 months to six months.
Onyx Pharmaceuticals: FDA grants priority review status colorectal cancer drug regorafenib
ReplyDeleteOnyx biopharmaceutical its partners Bayer (Bayer)'s Bayer HealthCare (Bayer Healthcare) jointly announced, FDA granted regorafenib (BAY 73-4506) priority review status.
Bayer Healthcare was submitted to the FDA by the end of April this year, regorafenib New Drug Application (NDA), for the illness after receiving standard therapy for metastatic colorectal cancer patients is still deteriorating.
Regorafenib oral medication is a multi-kinase inhibitor, the company is now a variety of cancer patients for clinical trials to investigate its therapeutic potential in research.
FDA grants priority review status for existing drugs usually with little or no appropriate therapies to treat the disease. In addition, priority review status means that medication review period from the standard 10 months to six months.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Tofacitinib
Fludarabine phosphate
Bardoxolone methyl
NSC 74859
Sorafenib Tosylate
SB-590885
Vemurafenib
Dabrafenib
GDC-0879
PLX-4720